Current Report Filing (8-k)

Date : 05/16/2019 @ 9:04PM
Source : Edgar (US Regulatory)
Stock : Vaxart, Inc. (VXRT)
Quote : 0.71  -0.0077 (-1.07%) @ 8:23PM

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 1 2 , 201 9

 

 

Vaxart, Inc.

(Exact name of registrant as specified in its charter)

 

 

         

Delaware

 

001-35285

 

59-1212264

(State or other jurisdiction   of incorporation)

 

(Commission   File Number)

 

(IRS Employer   Identification No.)

   

290 Utah Ave. Suite 200   South San Francisco, California

 

94080

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: ( 650) 550-3500

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading symbol

 

Name of each exchange on which registered

Common stock, $0.10 par value

 

VXRT

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers .

 

(e)

 

On May 12, 2019, the Board of Directors of Vaxart, Inc., upon the recommendation of the Compensation Committee, approved for our named executive officers (as set forth in our proxy statement for our Annual Meeting of Stockholders held on April 23, 2019) who are currently serving as executive officers: (i) annual base salaries, effective retroactively to January 1, 2019, (ii) target performance bonuses for 2019, and (iii) stock option grants pursuant to our 2019 Equity Incentive Plan, each as set forth below

 

Name

 

2019 Base Salary

 

Target Bonus %

 

2019 Target   Performance Bonus   Amount (1 )

 

Options Granted (2 )

 

Wouter W. Latour, M.D.

  President and Chief Executive Officer

 

$485,000

50%

$242,500

363,261

Sean N. Tucker, Ph.D.

  Chief Scientific Officer

$331,800

30%

$99,540

124,061

________________

 

(1)

Dr. Latour’s 2019 performance bonus will be based solely upon the achievement of corporate performance goals. The corporate performance goals relate to the advancement of our clinical trials, business and corporate development objectives, collaboration objectives and financial management objectives. Dr. Tucker’s 2019 performance bonus will be based upon the achievement of corporate performance goals (67%) and individual performance goals (33%). The individual performance goals will consist of a subjective assessment of Dr. Tucker’s individual contributions to Vaxart.

 

(2) The vesting commencement date of the grants was May 10, 2019 and the grants will vest as follows: 1/4 th of the shares will vest on the one year anniversary of the vesting commencement date, and 1/48 th of the shares will vest monthly for 36 months thereafter, in all cases subject to the continued service of the named executive officer.

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

             
 

 

 

 

Vaxart, Inc.

     

Dated: May 16, 2019

 

 

 

 
       
 

 

 

 

By:

 

/s/ Wouter W. Latour, M.D.

 
 

 

 

 

 

 

Wouter W. Latour, M.D.

 

 

 

 

 

 

President and Chief Executive Officer

 

Vaxart, Inc. (NASDAQ:VXRT)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more Vaxart, Inc. Charts.

Vaxart, Inc. (NASDAQ:VXRT)
Intraday Stock Chart

Today : Monday 22 July 2019

Click Here for more Vaxart, Inc. Charts.

Latest VXRT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.